Number of Benevolent Rounds
| Group | Value (number of rounds) | Spread |
|---|---|---|
| Oxytocin | 6.8 | 2.0 |
| Placebo | 6.8 | 2.3 |
Trial · Interventional
CompletedPhase 1Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Oxytocin is a neuropeptide that is well known for its role in social and affiliative behavior in humans. Oxytocin receptors are significantly lowered in autistic individuals and administration of oxytocin has shown benefits in enhancing social recognition and behavior in autistic children. However, more recent research has refined the behavioral effects of oxytocin, moving away from the notion that the neuropeptide blindly induces love and trust, towards the view that it actually increases social perception in assessing friend vs. foe: supporting cohesion with 'insiders' and distrust and aggression for 'outsiders.' Oxytocin is responsible for the selective aggression shown by lactating female mammals protecting their young, an effect demonstrated also in humans, and has been shown to strengthen feelings of ethnocentrism. However, no neuroimaging study to date has investigated this effect, with the consequence that its neurobiological basis is still unknown. The general aim of our study is to determine meso-circuit brain dynamics that underlie oxytocin's amplification of both trust and aggression; and specifically, using neuroimaging (fMRI, magnetoencephalography, and behavioral testing) whether oxytocin amplifies kinship bias by attenuating social reward learning.
Active comparator
Oxytocin
Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
Placebo comparator
Placebo
Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
Outcomes the sponsor listed as primary.
Number of Benevolent Rounds
Time frame · Immediately after completion of the study, for each subject.
This study recruited healthy adults. Subjects participated in an interactive neuroeconomic game, an iterative version of the classical "Trust Study." During this game, the subject ('investor') is first provided a sum of money (20 units). He then has the choice in terms of how much to invest in a fictional computer-generated trustee. The trustee then sends some percentage back to the subject ('investor'), and the game iterates over 20 trials (rounds). We computed the investment ratio as the ratio of the actual investment and the maximum allowed amount of 20 units, and analogously for the repayment ratio. Benevolent rounds were defined as those with increased investment ratios even after a decreased repayment ratio.
Number of Malevolent Rounds
Time frame · Immediately after completion of the study, for each subject.
This study recruited healthy adults. Subjects participated in an interactive neuroeconomic game, an iterative version of the classical "Trust Study." During this game, the subject ('investor') is first provided a sum of money (20 units). He then has the choice in terms of how much to invest in a fictional computer-generated trustee. The trustee then sends some percentage back to the subject ('investor'), and the game iterates over 20 trials (rounds). We computed the investment ratio as the ratio of the actual investment and the maximum allowed amount of 20 units, and analogously for the repayment ratio. Malevolent rounds were defined as those with decreased investment ratios even after an increased repayment ratio.
Functional Connectivity Between OFC and AMY
Time frame · Within two weeks of enrollment completion.
During functional scans, subjects participated in an interactive neuroeconomic game, an iterative version of the classical "Trust Study." Subjects participated in an interactive neuroeconomic game, an iterative version of the classical "Trust Study." During this game, the subject ('investor') is first provided a sum of money (20 units). He then has the choice in terms of how much to invest in a fictional computer-generated trustee. The trustee then sends some percentage back to the subject ('investor'), and the game iterates over 20 trials (rounds). Using Dynamical Causal Modeling (DCM) we modeled the dynamic interaction between amygdala (AMY), nucleus accumbens (NAcc) and the orbitofrontal cortex (OFC). We observed altered connectivity strength between AMY and OFC under OT as compared to PL conditions.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (number of rounds) | Spread |
|---|---|---|
| Oxytocin | 6.8 | 2.0 |
| Placebo | 6.8 | 2.3 |
| Group | Value (number of rounds) | Spread |
|---|---|---|
| Oxytocin | 2.8 | 1.5 |
| Placebo | 3.0 | 2.1 |
| Group | Value (Hz) | Spread |
|---|---|---|
| Oxytocin | 0.45 | NA |
| Placebo | 0.18 | NA |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Oxytocin, Then PlaceboSubjects who received oxytocin before their first scan, and placebo before their second scan. | – | 0 / 20 | 0 / 20 |
| Placebo, Then OxytocinSubjects who received placebo before their first scan, and oxytocin before their second scan. | – | 0 / 19 | 0 / 19 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
11 studies on this page
Indexing hint: Clinical trial · 2011
Bartz et al. 2011Social cognitive and affective neurosciencecited by 266
PMID 21115541PMC3190211DOI 10.1093/scan/nsq085PUB-21115541
Indexing hint: Randomized controlled trial · 2011
De Dreu et al. 2011Proceedings of the National Academy of Sciences of the United States of Americacited by 379
PMID 21220339PMC3029708DOI 10.1073/pnas.1015316108PUB-21220339
Indexing hint: Systematic review · 2011
MacDonald et al. 2011Psychoneuroendocrinologycited by 276
PMID 21429671DOI 10.1016/j.psyneuen.2011.02.015PUB-21429671
Indexing hint: Randomized controlled trial · 2010
Guastella et al. 2010Biological psychiatrycited by 686
PMID 19897177DOI 10.1016/j.biopsych.2009.09.020PUB-19897177
Indexing hint: Systematic review · 2009
Rossignol et al. 2009Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatristscited by 85
PMID 19917212DOI 10.1177/104012370902100404PUB-19917212
Indexing hint: Randomized controlled trial · 2008
Baumgartner et al. 2008Neuroncited by 700
PMID 18498743DOI 10.1016/j.neuron.2008.04.009PUB-18498743
Indexing hint: Randomized controlled trial · 2008
Singer et al. 2008Emotion (Washington, D.C.)cited by 172
PMID 19102589PMC2672051DOI 10.1037/a0014195PUB-19102589
Indexing hint: Randomized controlled trial · 2007
Domes et al. 2007Biological psychiatrycited by 826
PMID 17137561DOI 10.1016/j.biopsych.2006.07.015PUB-17137561
Indexing hint: Randomized controlled trial · 2007
Domes et al. 2007Biological psychiatrycited by 588
PMID 17617382DOI 10.1016/j.biopsych.2007.03.025PUB-17617382
Indexing hint: Clinical trial · 2005
Kosfeld et al. 2005Naturecited by 1,701
PMID 15931222DOI 10.1038/nature03701PUB-15931222
Indexing hint: Observational study · 2005
Kirsch et al. 2005The Journal of neuroscience : the official journal of the Society for Neurosciencecited by 1,030
PMID 16339042PMC6725903DOI 10.1523/jneurosci.3984-05.2005PUB-16339042
11 studies on this page
PubMed tag: none · 2010
Domes et al. 2010Psychoneuroendocrinologycited by 418
PMID 19632787DOI 10.1016/j.psyneuen.2009.06.016PUB-19632787
PubMed tag: none · 2010
Wermter et al. 2010American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Geneticscited by 116
PMID 19777562DOI 10.1002/ajmg.b.31032PUB-19777562
PubMed tag: none · 2010
Andari et al. 2010Proceedings of the National Academy of Sciences of the United States of Americacited by 637
PMID 20160081PMC2840168DOI 10.1073/pnas.0910249107PUB-20160081
Indexing hint: Review · 2010
Insel et al. 2010Neuroncited by 736
PMID 20346754PMC2847497DOI 10.1016/j.neuron.2010.03.005PUB-20346754
PubMed tag: none · 2010
Park et al. 2010Progress in neuro-psychopharmacology & biological psychiatrycited by 58
PMID 20347913DOI 10.1016/j.pnpbp.2010.03.029PUB-20347913
Indexing hint: Review · 2010
Averbeck et al. 2010Proceedings of the National Academy of Sciences of the United States of Americacited by 50
PMID 20448196PMC2889126DOI 10.1073/pnas.1004892107PUB-20448196
PubMed tag: none · 2010
Bartz et al. 2010Proceedings of the National Academy of Sciences of the United States of Americacited by 165
PMID 21115834PMC3003037DOI 10.1073/pnas.1012669107PUB-21115834
PubMed tag: none · 2010
Pincus et al. 2010Frontiers in psychiatrycited by 69
PMID 21423444PMC3059627DOI 10.3389/fpsyt.2010.00134PUB-21423444
PubMed tag: none · 2009
Gregory et al. 2009BMC medicinecited by 418
PMID 19845972PMC2774338DOI 10.1186/1741-7015-7-62PUB-19845972
PubMed tag: none · 2008
Delgado et al. 2008Neuroncited by 11
PMID 18498730DOI 10.1016/j.neuron.2008.05.005PUB-18498730
PubMed tag: none · 2008
Petrovic et al. 2008The Journal of neuroscience : the official journal of the Society for Neurosciencecited by 322
PMID 18579733PMC2647078DOI 10.1523/jneurosci.4572-07.2008PUB-18579733
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated